JNJ vs. RIGL

Last updated Jun 13, 2026

JNJ (Johnson & Johnson) and RIGL (Rigel Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — JNJ in Drug Manufacturers - General, RIGL in Biotechnology. Over the past 10 years, JNJ returned 10.46%/yr vs 3.28%/yr for RIGL. At a 0.17 correlation, their price movements are largely independent.

Performance

JNJ vs. RIGL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Johnson & Johnson (JNJ) and Rigel Pharmaceuticals, Inc. (RIGL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, JNJ achieves a 17.68% return, which is significantly higher than RIGL's -23.30% return. Over the past 10 years, JNJ has outperformed RIGL with an annualized return of 10.46%, while RIGL has yielded a comparatively lower 3.28% annualized return.

JNJ

• 1D: 1.07%
• 1M: 5.14%
• YTD: 17.68%
• 6M: 15.11%
• 1Y: 57.60%
• 3Y*: 17.82%
• 5Y*: 10.94%
• 10Y*: 10.46%

RIGL

• 1D: 2.40%
• 1M: 2.24%
• YTD: -23.30%
• 6M: -19.45%
• 1Y: 54.23%
• 3Y*: 27.10%
• 5Y*: -3.96%
• 10Y*: 3.28%

*Multi-year figures are annualized to reflect compound growth (CAGR)

JNJ vs. RIGL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
JNJ Johnson & Johnson	17.68%	47.48%	-4.81%	-8.58%	5.97%	11.44%	10.82%	16.22%	-5.13%	24.43%
RIGL Rigel Pharmaceuticals, Inc.	-23.30%	154.64%	16.00%	-3.33%	-43.40%	-24.29%	63.55%	-6.96%	-40.72%	63.03%

Correlation

The correlation between JNJ and RIGL is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.19
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.09
Correlation (10Y) Calculated over the trailing 10-year period	0.12
Correlation (All Time) Calculated using the full available price history since Nov 29, 2000	0.17

Fundamentals

Market Cap JNJ : $588.98B RIGL : $646.69M
EPS JNJ : $8.65 RIGL : $19.21
PE Ratio JNJ : 27.85 RIGL : 1.71
PEG Ratio JNJ : 0.93 RIGL : 0.00
PS Ratio JNJ : 6.08 RIGL : 2.08
PB Ratio JNJ : 7.25 RIGL : 1.62
Total Revenue (TTM) JNJ : $96.36B RIGL : $299.77M
Gross Profit (TTM) JNJ : $66.60B RIGL : $279.95M
EBITDA (TTM) JNJ : $31.62B RIGL : $125.80M

Return for Risk

JNJ vs. RIGL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JNJ

JNJ Risk / Return Rank: 96
JNJ Sharpe Ratio Rank: 97
JNJ Sortino Ratio Rank: 98
JNJ Omega Ratio Rank: 97
JNJ Calmar Ratio Rank: 93
JNJ Martin Ratio Rank: 94

RIGL

RIGL Risk / Return Rank: 67
RIGL Sharpe Ratio Rank: 68
RIGL Sortino Ratio Rank: 70
RIGL Omega Ratio Rank: 69
RIGL Calmar Ratio Rank: 65
RIGL Martin Ratio Rank: 61

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JNJ vs. RIGL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Johnson & Johnson (JNJ) and Rigel Pharmaceuticals, Inc. (RIGL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	JNJ	RIGL	Difference
Sharpe ratio: Return per unit of total volatility	3.42	0.78	+2.64
Sortino ratio: Return per unit of downside risk	4.94	1.64	+3.30
Omega ratio: Gain probability vs. loss probability	1.61	1.20	+0.41
Calmar ratio: Return relative to maximum drawdown	5.28	1.09	+4.19
Martin ratio: Return relative to average drawdown	15.52	1.91	+13.62

JNJ vs. RIGL - Sharpe Ratio Comparison

The current JNJ Sharpe Ratio is 3.42, which is higher than the RIGL Sharpe Ratio of 0.78. The chart below compares the historical Sharpe Ratios of JNJ and RIGL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

JNJ vs. RIGL - Drawdown Comparison

The maximum JNJ drawdown since its inception was -50.67%, smaller than the maximum RIGL drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for JNJ and RIGL.

Drawdown Indicators

	JNJ	RIGL	Difference
Max Drawdown Largest peak-to-trough decline	-50.67%	-99.37%	+48.70%
Max Drawdown (1Y) Largest decline over 1 year	-10.96%	-50.08%	+39.12%
Max Drawdown (3Y) Largest decline over 3 years	-15.95%	-57.75%	+41.80%
Max Drawdown (5Y) Largest decline over 5 years	-18.41%	-85.24%	+66.83%
Max Drawdown (10Y) Largest decline over 10 years	-27.37%	-86.40%	+59.03%
Current Drawdown Current decline from peak	-2.54%	-96.93%	+94.39%
Average Drawdown Average peak-to-trough decline	-11.90%	-90.91%	+79.01%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.72%	28.64%	-24.92%

Volatility

JNJ vs. RIGL - Volatility Comparison

The current volatility for Johnson & Johnson (JNJ) is 5.47%, while Rigel Pharmaceuticals, Inc. (RIGL) has a volatility of 12.05%. This indicates that JNJ experiences smaller price fluctuations and is considered to be less risky than RIGL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JNJ	RIGL	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.47%	12.05%	-6.58%
Volatility (6M) Calculated over the trailing 6-month period	12.16%	36.64%	-24.48%
Volatility (1Y) Calculated over the trailing 1-year period	16.94%	69.89%	-52.95%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.87%	85.46%	-68.59%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.48%	82.81%	-64.33%

Dividends

JNJ vs. RIGL - Dividend Comparison

JNJ's dividend yield for the trailing twelve months is around 2.18%, while RIGL has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
JNJ Johnson & Johnson	2.18%	2.48%	3.40%	3.00%	2.52%	2.45%	2.53%	2.57%	2.74%	2.38%	2.73%	2.87%
RIGL Rigel Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

JNJ vs. RIGL - Profitability Comparison

The chart below illustrates the profitability comparison between Johnson & Johnson and Rigel Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a gross profit of 17.20B and revenue of 24.06B. Therefore, the gross margin over that period was 71.5%.

RIGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported an operating income of 6.40B and revenue of 24.06B, resulting in an operating margin of 26.6%.

RIGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a net income of 5.24B and revenue of 24.06B, resulting in a net margin of 21.8%.

RIGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.

Frequently Asked Questions

Can I hold both JNJ and RIGL in my portfolio?

JNJ and RIGL have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, JNJ or RIGL?

RIGL has higher volatility (12.05%) compared to JNJ (5.47%). In terms of maximum drawdown, JNJ dropped -50.67% vs RIGL's -99.37%.

Which has better risk-adjusted returns?

JNJ currently has the higher Sharpe Ratio (3.42 vs 0.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.